Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
A definition of "flare" in patients with rheumatoid arthritis (RA) was recently announced. 1 This definition uses the simplified disease activity index (SDAI) and clinical disease activity index (CDAI).The paper emphasizes its reliability as a material for determining withdrawal conditions in studies such as clinical trials and for an endpoint of the drug tapering process. Still, more importantly, flare can be determined immediately in front of the patient in a clinical setting.Before the definition, poor disease control was an indicator of transition to phase 2. However, the judgment relied on each institution or rheumatologist, 2,3 so the flare differed. After publication, French cohort studies reported that the definition helped identify the risk of poor disease control. 4 By defining flare, we can appropriately determine when to intervene with effective biological or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsD-MARDs) when moving to phase 2. This study evaluated whether the definition functions effectively as a decision to move to phase 2 or later using a real-world small cohort dataset.Japanese patients with RA who met the 2010 EULAR/ACR classification criteria 5 and followed up for more than three consecutive years from August 2010 to April 2020, following EULAR recommendations for RA since 2010 and every 3 years, were recruited in the study. 6 Patients who censored withdrawal by admission for reasons other than disease control worsening, such as severe infections and worsening of comorbidities, at death for any reasons, or temporally dropping out following up for any reasons by the date of 3 years from
A definition of "flare" in patients with rheumatoid arthritis (RA) was recently announced. 1 This definition uses the simplified disease activity index (SDAI) and clinical disease activity index (CDAI).The paper emphasizes its reliability as a material for determining withdrawal conditions in studies such as clinical trials and for an endpoint of the drug tapering process. Still, more importantly, flare can be determined immediately in front of the patient in a clinical setting.Before the definition, poor disease control was an indicator of transition to phase 2. However, the judgment relied on each institution or rheumatologist, 2,3 so the flare differed. After publication, French cohort studies reported that the definition helped identify the risk of poor disease control. 4 By defining flare, we can appropriately determine when to intervene with effective biological or targeted synthetic disease-modifying anti-rheumatic drugs (b/tsD-MARDs) when moving to phase 2. This study evaluated whether the definition functions effectively as a decision to move to phase 2 or later using a real-world small cohort dataset.Japanese patients with RA who met the 2010 EULAR/ACR classification criteria 5 and followed up for more than three consecutive years from August 2010 to April 2020, following EULAR recommendations for RA since 2010 and every 3 years, were recruited in the study. 6 Patients who censored withdrawal by admission for reasons other than disease control worsening, such as severe infections and worsening of comorbidities, at death for any reasons, or temporally dropping out following up for any reasons by the date of 3 years from
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.